Dapagliflozin/sitagliptin

Dapagliflozin/sitagliptin, sold under the brand name Sidapvia, is a fixed-dose combination anti-diabetic medication used for the treatment of type 2 diabetes.^[1] It contains dapagliflozin, as propanediol monohydrate, a SGLT-2 inhibitor; and sitagliptin, as phosphate monohydrate, a DPP-4 inhibitor.^[1] It is taken by mouth.^[1]

Dapagliflozin/sitagliptin

Combination of
Dapagliflozin	SGLT-2 inhibitor
Sitagliptin	DPP-4 inhibitor
Clinical data
Trade names	Sidapvia
Pregnancy category	AU: D[1]
Routes of administration	By mouth
ATC code	A10BD29 (WHO)
Legal status
Legal status	AU: S4 (Prescription only)[1][2][3] KR: Rx-only[4]

References

1. "TGA eBS - Product and Consumer Medicine Information Licence". Archived from the original on 8 July 2024. Retrieved 8 July 2024.
2. "Sidapvia (AstraZeneca Pty Ltd)". Therapeutic Goods Administration (TGA). 1 July 2024. Archived from the original on 7 July 2024. Retrieved 8 July 2024.
3. "Sidapvia 10/100 dapagliflozin 10 mg (as propanediol monohydrate)/sitagliptin 100 mg (as phosphate monohydrate) film coated tablets blister pack (405540)". Therapeutic Goods Administration (TGA). 8 June 2024. Archived from the original on 8 July 2024. Retrieved 8 July 2024.
4. Dunleavy K (24 July 2023). "AstraZeneca enlists SK Chemicals to produce diabetes combo drug Sidapvia". Fierce Pharma. Retrieved 8 July 2024.